MB, Yes you are correct, I was using some poetic license. So if nothing more were signed would be tied for first place. In terms of Lilly we know that they will be moving to Phase III on Donanemab and we know that Cogstate should get the contract, firstly because they are Lillys officially preferred partner for Cognition and secondly because they did the phase II you would not want to change that.
We should know a lot more about Lillys plans and the Phase II results of Donanemab in the next few days. Lilly will present data on 13th March at 15th International Conference on Alzheimer's & Parkinson Diseases. That said I would expect them to move quickly in to Phase III as they do not want Aducanumab to get too much of head start.
CGS Price at posting:
$1.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)